The standard treatment time of targeted therapy for patients with initial diagnosis of breast cancer is within 1 year after surgery, if the drug is used once in 3 weeks, the total treatment cycle is 17 times, this is only the general situation, the specific drug use needs to be combined with the patient’s pathological type, molecular typing and other conditions to make a comprehensive analysis and judgment, it is recommended that patients must listen to the professional doctor’s advice for standardized diagnosis and treatment. For some patients with advanced breast cancer or recurrent metastases, who have failed to survive chemotherapy or endocrine therapy and choose targeted therapy, the number of targeted therapy is not exactly in accordance with the cycle of the initial treatment plan, and the treatment plan should be formulated according to the patient’s condition. During the period of targeted therapy, such patients need to be closely reviewed, observe the changes of indicators, and carry out long-term continuation of targeted therapy until the clinical indication of treatment failure, then the targeted drug therapy can be stopped. Therefore, the number of targeted therapy for this group of patients cannot be judged. In addition, targeted therapy for anti-Her-2(+) patients can also be combined with radiotherapy and chemotherapy, which can act more precisely on the target and play an anti-tumor role.